Daniel J. O'Connor
CIK 1376847 · President and CEO · last filed 2026-06-03
Daniel J. O'Connor is a President and CEO who has filed 87 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for DMAC, was dated Jun 3, 2026. Across all open-market trades the lifetime net is −$845.8K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
8
87
-$845.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DMAC | Director | 0 | $5.65 | $0 | $0 | 2 | 2026-06-03 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | President and CEO | 0 | $28.00 | $0 | -$491.1K | 5 | 2024-03-07 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | 16,000 | $0.39 | $6.2K | $9.8K | 7 | 2024-01-08 |
| ZyVersa Therapeutics, Inc. (LSPRW) Delisted | Chief Executive Officer | 42,005 | $0.18 | $7.6K | $0 | 1 | 2022-03-10 |
| ONCOSEC MEDICAL Inc (ONCS) Delisted | CEO and President | 96,097 | $0.28 | $26.6K | -$48.5K | 18 | 2021-05-04 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Chief Executive Officer | 618,352 | — | — | -$68.6K | 11 | 2017-07-03 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Executive Officer | 302,710 | — | — | -$247.4K | 39 | 2016-10-04 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | SVP, Interim Gen. Counsel, Sec | — | — | — | $0 | 2 | 2007-02-21 |
Recent Filings
87 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | DMAC | Grant (A) | — | $0 | EDGAR |
| 2025-02-24 | DMAC | Grant (A) | — | $0 | EDGAR |
| 2024-03-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Disp (D) | −48,202 | $0 | EDGAR |
| 2024-01-08 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-11 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +750,000 | $0 | EDGAR |
| 2023-10-31 | Ambrx Biopharma, Inc. (AMAM) Delisted | Sell (S) | −50,012 | -$491.1K | EDGAR |
| 2023-07-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-04-28 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +2,750,000 | $0 | EDGAR |
| 2023-01-05 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-02 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Buy (P) | +16,000 | $9.8K | EDGAR |